接种BNT162b2或mRNA-1273疫苗后突发性感音神经性听力损失:一项丹麦全国性人群队列研究
该全国性队列研究比较了接种BNT162b2或mRNA-1273疫苗者与未接种者突发性感音神经性听力损失的发生情况。结果显示接种疫苗与突发性感音神经性听力损失(校正HR 0.99,CI 0.59-1.64)或前庭神经炎(校正HR 0.94,CI 0.69-1.24)风险增加无关,但接种后21天内因耳鼻咽喉科就诊并开具中高剂量泼尼松龙的风险略有增加(校正HR 1.40,CI 1.08-1.81)。
要点
- 接种BNT162b2或mRNA-1273疫苗未增加突发性感音神经性听力损失风险(校正HR 0.99,CI 0.59-1.64)。
- 接种疫苗未增加前庭神经炎风险(校正HR 0.94,CI 0.69-1.24)。
- 接种后21天内耳鼻咽喉科就诊并开具中高剂量泼尼松龙的风险略有增加(校正HR 1.40,CI 1.08-1.81)。
核心结论
- 研究结果提示接种mRNA新冠疫苗后突发性感音神经性听力损失或前庭神经炎的风险未见增加。
- mRNA新冠疫苗接种可能与耳鼻咽喉科就诊并开具中高剂量泼尼松龙的轻微超额风险相关。
研究设计与样本
- 研究设计为队列研究,基于丹麦全国健康登记数据,纳入2020年10月1日居住在丹麦且年满18岁或2021年满18岁的所有丹麦居民。
- 比较接种BNT162b2或mRNA-1273疫苗(第一、第二或第三剂)后与未接种者人时中突发性感音神经性听力损失的发生情况。
- 次要结局为首次因前庭神经炎住院诊断,以及耳鼻咽喉科专家听力检查后开具中高剂量泼尼松龙处方。
主要发现
- 接种BNT162b2或mRNA-1273疫苗与突发性感音神经性听力损失出院诊断风险无关(校正HR 0.99,CI 0.59-1.64)。
- 接种疫苗与前庭神经炎风险无关(校正HR 0.94,CI 0.69-1.24)。
- 接种mRNA新冠疫苗后21天内因耳鼻咽喉科就诊并开始中高剂量口服泼尼松龙的风险略有增加(校正HR 1.40,CI 1.08-1.81)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the occurrence of sudden sensorineural hearing loss following immunization with BNT162b2 (Comirnaty®; Pfizer BioNTech) or mRNA-1273 (Spikevax®; Moderna) to the occurrence among unvaccinated individuals. STUDY DESIGN: Cohort study. SETTING: Nationwide Danish health care registers comprised all Danish residents living in Denmark on October 1, 2020, who were 18 years or older or turned 18 in 2021. METHODS: We compared the occurrence of sudden sensorineural hearing loss following immunization with BNT162b2 (Comirnaty®; Pfizer BioNTech) or mRNA-1273 (Spikevax®; Moderna) (first, second, or third dose) against unvaccinated person time. Secondary outcomes were a first-ever hospital diagnosis of vestibular neuritis and a hearing examination, by an ear-nose-throat (ENT) specialist, followed by a prescription of moderate to high-dose prednisolone. RESULTS: BNT162b2 or mRNA-1273 vaccine was not associated with an increased risk of receiving a discharge diagnosis of sudden sensorineural hearing loss (adjusted hazard ratio [HR]: 0.99, confidence interval [CI]: 0.59-1.64) or vestibular neuritis (adjusted HR: 0.94, CI: 0.69-1.24). We found a slightly increased risk (adjusted HR: 1.40, CI, 1.08-1.81) of initiating moderate to high-dose oral prednisolone following a visit to an ENT specialist within 21 days from receiving a messenger RNA (mRNA)-based Covid-19 vaccine. CONCLUSION: Our findings do not suggest an increased risk of sudden sensorineural hearing loss or vestibular neuritis following mRNA-based COVID-19 vaccination. mRNA-Covid-19 vaccination may be associated with a small excess risk of a visit to an ENT specialist visit followed by a prescription of moderate to high doses of prednisolone.
引用
- Damkier P, Cleary B, Hallas J, et al. Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273: A Danish Population-Based Cohort Study. Otolaryngol Head Neck Surg. 2023. PMID: 37288514. doi:10.1002/ohn.394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。